Every material Form 8-K Aveanna Healthcare Holdings, Inc. has filed with the SEC since August 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Aveanna Healthcare director Steven E. Rodgers, a Class II director who sat on the Audit and Compensation Committees, resigned from the board effective immediately, as disclosed in an October 2, 2026 filing. The company said the resignation was not due to any disagreement on operations, policies, or practices, and the filing does not name a replacement.
Steven E. Rodgers notified the company of his resignation on October 1, 2026, effective immediately.
He was an independent Class II director serving on the Audit Committee and the Compensation Committee.
The company states the resignation was not due to any disagreement with the company on operations, policies, or practices.
The filing does not name a successor or new committee assignments.
Aveanna Healthcare Holdings disclosed an underwriting agreement dated August 20, 2026, for a secondary offering of 15,000,000 shares of common stock by certain selling stockholders, including affiliates of J.H. Whitney Equity Partners VII, LLC, at $11.75 per share. The offering closed on August 24, 2026, and the company received no proceeds, so the sale adds shares held by the public without new capital for the company.
Selling stockholders offered 15,000,000 shares at a public offering price of $11.75 per share, with RBC Capital Markets, LLC as underwriter.
The underwriter received a 30-day option to buy up to an additional 2,250,000 shares from the selling stockholders.
The secondary offering closed on August 24, 2026; the company did not issue or sell any shares and received no proceeds.
Aveanna Healthcare filed an August 2026 investor presentation under Form 8-K showing second-quarter 2026 revenue of $670.5 million, up 13.7% from $589.6 million a year earlier. Adjusted EBITDA, a non-GAAP measure, rose 8.0% to $95.4 million, though gross margin as a percentage of revenue was lower than in the prior-year quarter, and the company reiterated 2026 guidance of more than $2.68 billion in revenue and more than $365 million in adjusted EBITDA.
Q2 2026 revenue $670.5 million, up 13.7% from $589.6 million in Q2 2025
Q2 2026 gross margin $218.5 million, up 3.7%; adjusted EBITDA $95.4 million, up 8.0%
Free cash flow of $75.4 million for 2026 to date, a $38.5 million improvement over 2025
2026 guidance: revenue above $2.68 billion and adjusted EBITDA above $365 million
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Aveanna Healthcare Holdings, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →